ATS Corporation's first quarter under new CEO Doug Wright arrived with the market in a punishing mood and the company with a story to tell. The headline was punishing: revenue fell 5.8% to $693.7M (CAD; $499.9M USD) from $736.7M ($530.9M USD) a year ago, the company slipped to a $0.3M ($0.2M USD) net loss from $24.3M of net income, and the stock dropped about 26% on the 8/6 release day - from $27.95 to $20.53 - before bottoming at a fresh 52-week low of $19.73 on 8/10. The clean read on the quarter, though, is a different one. Adjusted earnings from operations fell 13.4% to $68.1M ($49.1M USD) at a 9.8% margin (down 92 basis points), and the company announced an 18-month Fixed Cost Transformation Program aimed at extracting roughly half the cost savings needed to reach its long-term 15% adjusted-earnings-from-operations margin target. The market sold the deceleration. The company sold the strategy.
Three things landed in the same print and they reinforce each other. The operational reset is the most consequential: gross margin on adjusted revenues (excluding adjustment items) improved both sequentially and year-over-year, even as the headline margin compressed on $28.5M ($20.5M USD) of one-time items related to the previously announced transportation reorganization, a fresh services-business reorganization, a software-business impairment, and a CEO-inducement charge. Strip those out and the core business earned more on every revenue dollar than a year ago. The end-market mix is reshaping on a multi-quarter timeline. Life sciences still drove 49.5% of revenue at $345.9M ($249.2M USD) but contracted 8.7% as GLP-1-related demand normalized and project timing slipped; energy nearly doubled to $59.8M ($43.1M USD) on nuclear-refurbishment execution; services revenue rose 11.4% to $182.8M ($131.7M USD) on installed-base growth. The Fixed Cost Transformation Program is the new strategic commitment: an 18-month, multi-phase effort beginning with the European Footprint Consolidation (a $20M annual cost reduction in phase one, representing roughly 30% of total program savings) and a clear, quantified half-the-margin-expansion contribution toward the 15% long-term target.
The price reaction is what it is. At $20.31 USD (8/14/2026 close, equivalent to $28.19 CAD at 0.7206), ATS trades at roughly 1.34x trailing revenue - well inside the industrial-automation peer band, and at a 9.7x EV-to-trailing-twelve-month-adjusted-EBITDA basis (using the company's own pro forma adjusted EBITDA of $404.3M CAD) that the market is paying for the execution risk on the cost program and the timing slip in life-sciences order conversion. The 52-week range of $19.14 to $35.82 USD marks the recent peak in May 2026 - pre-Q1 release - and a 52-week low in the days after. The market is pricing the cash drag, the backlog burn, and the CEO transition all at once. The Q1 print is a transitional quarter; the question is whether Q2 - the first quarter with a clean comparison base for the new restructuring items - confirms that the operational turn is already in the line.